HARM REDUCTION GROUP AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1475 SEK | +17.06% |
|
+13.03% | +1.03% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 188 | 121.3 | 43.41 | 43.41 | - |
| Enterprise Value (EV) 1 | 188 | 144 | 57.15 | 43.41 | 43.41 |
| P/E ratio | -11.1 x | -20.6 x | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.67 x | 0.25 x | 0.16 x | 0.12 x |
| EV / Revenue | - | 0.79 x | 0.34 x | 0.16 x | 0.12 x |
| EV / EBITDA | - | 11.5 x | -13.7 x | 3.31 x | 1.89 x |
| EV / FCF | - | -5,252,408 x | - | - | - |
| FCF Yield | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 211,234 | 294,303 | 294,303 | 294,303 | - |
| Reference price 2 | 0.8900 | 0.4120 | 0.1475 | 0.1475 | 0.1475 |
| Announcement Date | 2/28/22 | 2/28/23 | 2/28/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 181.8 | 168.6 | 271.1 | 353.6 |
| EBITDA 1 | - | 12.51 | -4.171 | 13.1 | 23 |
| EBIT 1 | - | -4.179 | -21.74 | -4.9 | 4.8 |
| Operating Margin | - | -2.3% | -12.9% | -1.81% | 1.36% |
| Earnings before Tax (EBT) 1 | - | -7.115 | -24.71 | -8 | - |
| Net income 1 | -11.4 | -7.115 | -24.71 | -6 | 1 |
| Net margin | - | -3.91% | -14.66% | -2.21% | 0.28% |
| EPS | -0.0800 | -0.0200 | - | - | - |
| Free Cash Flow | - | -27.42 | - | - | - |
| FCF margin | - | -15.08% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/28/24 | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | 49.54 | 41.07 | 40.36 | 45.64 | 41.5 |
| EBITDA 1 | 2.834 | 0.959 | -1.28 | 0.251 | -3.65 |
| EBIT 1 | -1.35 | -3.456 | -5.673 | -4.114 | -8.051 |
| Operating Margin | -2.73% | -8.42% | -14.06% | -9.01% | -19.4% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/28/23 | 5/31/23 | 8/30/23 | 11/29/23 | 2/28/24 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 22.8 | 14.2 | - | - |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.822 x | -3.401 x | - | - |
| Free Cash Flow | - | -27.4 | - | - | - |
| ROE (net income / shareholders' equity) | - | -14.2% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | 5 | - | - | - |
| Capex / Sales | - | 2.75% | - | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/28/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.03% | 4.02M | |
| -1.16% | 151M | |
| -19.03% | 99.53M |
- Stock Market
- Equities
- NOHARM Stock
- Financials Harm Reduction Group AB
